Skip to content
Triangle logo TriangleGet started
← Study library

NCT00002558 · REGISTRY CONDITION SEARCH

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2016-05-23

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support. PURPOSE: The purpose of this study is to determine the effects of an intensive sequence of chemotherapy drugs in patients with metastatic germ cell cancer. All of these chemotherapy drugs are known to be active in this disease.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Overall Objective Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion criteria: * Male/Female with histologically confirmed GCT with review by the Department of Pathology at this center. * Patients with advanced GCT, including patients with: measurable or evaluable disease, * patients with only elevated serum tumor markers (AFP and/or HCG), or * patients with known residual disease after postchemotherapy surgery. Eligible patients must have established clinical resistance to cisplatin by their failure to achieve a durable CR to a cisplatin-based regimen. * Prior treatment limited to ≤ 6 prior cycles (≤ four cycles preferred) of cisplatin. (GROUP A) * Prior therapy \> 6 cycles of cisplatin. (GROUP B) * Therapy must have been discontinued at least 3 weeks before entry onto protocol. * Patients must have one or more unfavorable prognostic factors for achieving a CR to cisplatin-based salvage therapy. These are: * Extragonadal primary site. * Testis/ovarian primary site with the best response of an IR to first-line therapy, or a partial response with normal tumor markers of six months or less in duration. * Prior treatment with ifosfamide-containing therapy * General medical condition sufficient to allow for general anesthesia at the time of pheresis catheter placement. * Patients must have negative serology for Human Immunodeficiency Virus. * Laboratory criteria for protocol entry: WBC ≥ 3000/ul Platelets 3 100,000/ul Cr Clearance \> 50 cc/min\* \* (unless renal dysfunction is due to tumor obstructing the ureters in which case eligibility will be determined by the Principal Investigator). * Age ≥ 15 years. * Signed informed consent. Exclusion Criteria: * Presence of active infection * Concurrent treatment with chemotherapy or * Inability to comply with the treatment protocol or to undergo the specified follow-up tests for safety or effectiveness. * Prior high-dose therapy with AuBMT. * Patients must have recovered from recent surgery.
healthy Volunteers
false
minimum Age
15 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support.
    intervention Names
    1. Biological: filgrastim
    2. Drug: carboplatin
    3. Drug: etoposide
    4. Drug: ifosfamide
    5. Drug: paclitaxel
    6. Procedure: peripheral blood stem cell transplantation
    label
    chemotherapy administered with G-CSF and PBSC support
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    filgrastim
    type
    BIOLOGICAL
  2. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    carboplatin
    type
    DRUG
  3. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    etoposide
    type
    DRUG
  4. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    ifosfamide
    type
    DRUG
  5. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    paclitaxel
    type
    DRUG
  6. arm Group Labels
    1. chemotherapy administered with G-CSF and PBSC support
    name
    peripheral blood stem cell transplantation
    type
    PROCEDURE
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
108
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Overall Objective Response will be assessed prior to dose-intensive therapy and at the completion of therapy. Complete disappearance of all clinical, radiographic and biochemical (normal AFP and HCG) evidence of disease for a minimum of 4 weeks (CR to chemotherapy). Patients must be free of disease for a minimum of 4 weeks. Partial Response: Complete disappearance of all biochemical evidence of disease in patients without a surgical procedure for a residual radiographic mass. Patients must demonstrate no biochemical recurrence or progression of radiographic masses for a minimum of four weeks (PR to chemotherapy}
    measure
    Overall Objective Response
    time Frame
    2 years
Full study description
brief Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administered with G-CSF and PBSC support. PURPOSE: The purpose of this study is to determine the effects of an intensive sequence of chemotherapy drugs in patients with metastatic germ cell cancer. All of these chemotherapy drugs are known to be active in this disease.
detailed Description
OBJECTIVES: * Determine the safety of paclitaxel and ifosfamide followed by carboplatin and etoposide with stem cell support in patients with unfavorable germ cell tumors with unfavorable prognostic factors and resistance to cisplatin. * Determine the efficacy of this regimen as salvage therapy in these patients. * Escalate the dose of carboplatin based on a target area under the concentration time curve and renal function, and determine the pharmacokinetics of carboplatin in selected patients. * Determine the qualitative effects of paclitaxel and ifosfamide on hematopoietic progenitors in these patients. OUTLINE: This is a dose escalation study of carboplatin. * Part A: Patients receive paclitaxel IV continuously on day 1 and ifosfamide IV over 4 hours on days 2-4. Autologous peripheral blood stem cells (PBSC) are harvested on days 11-13. Filgrastim (G-CSF) is administered subcutaneously (SC) twice daily beginning 6 hours after completion of paclitaxel and ifosfamide infusions and continuing until the last day of leukapheresis. Treatment continues every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Before beginning the first course of chemotherapy, autologous bone marrow (ABM) is harvested, if possible, in case insufficient peripheral blood stem cells (PBSC) are harvested. Patients who were unable to undergo harvest of ABM before the first course of chemotherapy undergo harvest of ABM before beginning the second course of chemotherapy. * Part B : Beginning 2 weeks after completion of regimen A, patients receive etoposide IV over 2 hours and carboplatin IV over 1 hour on days 1-3. PBSC are reinfused on day 5. G-CSF is administered SC twice daily beginning 6 hours after completion of etoposide and carboplatin infusions and continuing until blood counts recover. G-CSF is held on the morning of PBSC transplantation and restarted beginning 6 hours after completion of PBSC transplantation. Treatment continues every 2 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients with insufficient PBSC for the second course receive PBSC combined with ABM. Patients with insufficient PBSC for the third course receive ABM. During the second part, cohorts of 3-6 patients receive escalating doses of carboplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose-limiting toxicity. After completion of parts A and B, some patients may undergo resection of residual masses.
Source references
references
  1. citation
    Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Reich LM, Bosl GJ, Motzer RJ. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010 Apr 1;28(10):1706-13. doi: 10.1200/JCO.2009.25.1561. Epub 2010 Mar 1.
    pmid
    20194867
    type
    RESULT
  2. citation
    Kondagunta GV, Bacik J, Sheinfeld J, Bajorin D, Bains M, Reich L, Deluca J, Budnick A, Ishill N, Mazumdar M, Bosl GJ, Motzer RJ. Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors. J Clin Oncol. 2007 Jan 1;25(1):85-90. doi: 10.1200/JCO.2006.06.9401.
    pmid
    17194908
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-63537b4a4d47e5b252e9
      requested nct id
      NCT00002558
      primary nct id
      NCT00002558
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      payload sha256
      18a5eb37e6cf086dc82fb3d5869f1a24cca84f8903fc1bd5f7272389db2b166a
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-63537b4a4d47e5b252e9
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00002558
      occurrences
      1. context exact
        NCT00002558
        end
        11
        exact text
        NCT00002558
        start
        0
      offset unit
      unicode_code_points
      query cond
      Testicular Cancer
      query disease state id
      ds-testicular-cancer
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-testicular-cancer-000.json
      source file sha256
      9e542f373b689060c2c6c67507f6e2a629c92470fc1ae13d9359244ba59cb6b8
      source json pointer
      /studies/62/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e975f9dd9718c01240a16a28165c2c3aa0042d1f24ea3db9d43d7c960e95c89b
    2. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-c5d316052cc70ea5c851
      requested nct id
      NCT00002558
      primary nct id
      NCT00002558
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      a10e8ef1fa9256ee3fc97c8f1232aa3fc01529e26a627718afd38186807a7f67
      payload sha256
      59e946891a5be5e20e2aa6404ffa7eaa8b6484bda2cf41edab976f150623b87a
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-c5d316052cc70ea5c851
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00002558
      occurrences
      1. context exact
        NCT00002558
        end
        11
        exact text
        NCT00002558
        start
        0
      offset unit
      unicode_code_points
      query cond
      Extragonadal Germ Cell Tumors
      query disease state id
      ds-extragonadal-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-extragonadal-germ-cell-tumors-000.json
      source file sha256
      a10e8ef1fa9256ee3fc97c8f1232aa3fc01529e26a627718afd38186807a7f67
      source json pointer
      /studies/16/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e975f9dd9718c01240a16a28165c2c3aa0042d1f24ea3db9d43d7c960e95c89b
    3. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-f4dc72941c895146d45d
      requested nct id
      NCT00002558
      primary nct id
      NCT00002558
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      payload sha256
      64873aa760347d702c72b21b53c86314fd0e542d58ff37f34c23543594d6c815
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-f4dc72941c895146d45d
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00002558
      occurrences
      1. context exact
        NCT00002558
        end
        11
        exact text
        NCT00002558
        start
        0
      offset unit
      unicode_code_points
      query cond
      Ovarian Germ Cell Tumors
      query disease state id
      ds-ovarian-germ-cell-tumors
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-ovarian-germ-cell-tumors-000.json
      source file sha256
      359ee71d54598877a70c4f96300e96532a9c096cf831e27a29687916b1e2237d
      source json pointer
      /studies/83/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e975f9dd9718c01240a16a28165c2c3aa0042d1f24ea3db9d43d7c960e95c89b

    Preserved source evidence · Not medical advice